Association of NTproBNP in metabolic syndrome

Ipsita Dash; Ursula  Sampson; Pratima Kumari Sahu; Sumanth Kumar; Om Padarabinda Dash

doi:10.53730/ijhs.v6nS5.9149

Authors

Ipsita Dash Assistant professor, Department of Biochemistry, SLN MCH Koraput, PhD Scholar Meenakshi Medical College, Chennai
Ursula Sampson HOD Biochemistry, Meenakshi Medical College, Chennai
Pratima Kumari Sahu HOD Biochemistry, SCB Medical College, Cuttack
Sumanth Kumar Associate Professor, Department of Biochemistry, Meenakshi Medical College, Chennai
Om Padarabinda Dash
drompadarabindadash@gmail.com
Post PG SR, Pulmonary Medicine, Vimsar Burla

Keywords:

BMI, Metabolic syndrome, NT-pro BNP, SBP, DBP

Abstract

Aim: The association between NTpro BNP values and different biochemical and anthropometric parameters of metabolic syndrome patients and non-metabolic syndrome individuals are correlated here. Methods: The research involved 200 people aged 21 to 60 years old (100 control and 100 cases). The following measurements were taken- FBS, SBP, DBP, BMI, and lipid profile. Using multiple regression, we examined the correlation between NTproBNP and metabolic syndrome and non-metabolic syndrome patients. Correlation of Metabolic syndrome parameters with NTproBNP values are done. Result: NT pro BNP values are higher in metabolic syndrome patients in comparison to non-Metabolic syndrome patients. NTproBNP values are positively correlated with SBP, TG, LDL values in metabolic syndrome patients. Conclusion: NT pro BNP values are higher in metabolic syndrome patients in comparison to non-Metabolic syndrome patients.

Downloads

Download data is not yet available.

References

Wang TJ, Larson MG, Levy D, Benjamin EJ, Leip EP, Wilson PW, Vasan RS. Impact of obesity on plasma natriuretic peptide levels. Circulation. 2004; 109:594–600.

Das SR, Drazner MH, Dries DL, Vega GL, Stanek HG, Abdullah SM, Canham RM, Chung AK, Leonard D, Wians FH Jr, de Lemos JA. Impact of body mass and body composition on circulating levels of natriuretic peptides: results from the Dallas Heart Study. Circulation. 2005; 112:2163–8.

Costello-Boerrigter LC, Boerrigter G, Redfeld MM, Rodehefer RJ, Urban LH, Mahoney DW, Jacobsen SJ, Heublein DM, Burnett JC Jr. Aminoterminal pro-B-type natriuretic peptide and B-type natriuretic peptide in the general community: determinants and detection of left ventricular dysfunction. J Am Coll Cardiol. 2006; 47:345–53.

Sugisawa T, Kishimoto I, Kokubo Y, Makino H, Miyamoto Y, Yoshimasa Y. Association of plasma B-type natriuretic peptide levels with obesity in a general urban Japanese population: the Suita Study. Endocr J. 2010; 57:727–33.

Clerico A, Giannoni A, Vittorini S, Emdin M. The paradox of low BNP levels in obesity. Heart Fail Rev. 2012; 17:81–96.

Ricci MA, De Vuono S, Pucci G, Di Filippo F, Berisha S, Gentili A, et al. Determinants of low levels of brain natriuretic peptide in morbid obesity. Clin Nutr. 2017; 36:1075–1081.

Lavie CJ, Sharma A, Alpert MA, De Schutter A, Lopez-Jimenez F, Milani RV, et al. Update on obesity and obesity paradox in heart failure. Prog Cardiovasc Dis. 2016; 58:393–400.

Ndumele CE, Matsushita K, Sang Y, Lazo M, Agarwal SK, Nambi V, Deswal A, Blumenthal RS, Ballantyne CM, Coresh J, Selvin E. N-terminal pro-brain natriuretic peptide and heart failure risk among individuals with and without obesity: the Atherosclerosis Risk in Communities (ARIC) Study. Circulation. 2016; 133:631–8.

Wirth J, Buijsse B, di Giuseppe R, Fritsche A, Hense HW, Westphal S, Isermann B, Boeing H, Weikert C. Relationship between N-terminal pro-brain natriuretic peptide, obesity and the risk of heart failure in middle-aged German adults. PLoS ONE. 2014;9: e113710.

Madamanchi C, Alhosaini H, Sumida A, Runge MS. Obesity and natriuretic peptides, BNP and NT-proBNP: mechanisms and diagnostic implications for heart failure. Int J Cardiol. 2014; 176:611–7.

Lazo M, Young JH, Brancati FL, Coresh J, Whelton S, Ndumele CE, Hoogeveen R, Ballantyne CM, Selvin E. N-terminal pro-brain natriuretic peptide and risk of diabetes. Diabetes. 2013; 62:3189–93.

Magnusson M, Jujic A, Hedblad B, Engström G, Persson M, Struck J, Morgenthaler NG, Nilsson P, Newton-Cheh C, Wang TJ, Melander O. Low plasma level of atrial natriuretic peptide predicts development of diabetes: the prospective Malmo Diet and Cancer study. J Clin Endocrinol Metab. 2012; 97:638–45.

Brutsaert EF, Biggs ML, Delaney JA, Djoussé L, Gottdiener JS, Ix JH, Kim F, Mukamal KJ, Siscovick DS, Tracy RP, de Boer IH, deFilippi CR, Kizer JR. Longitudinal assessment of N-terminal pro-B-type natriuretic peptide and risk of diabetes in older adults: the cardiovascular health study. Metabolism. 2016; 65:1489–97.

Khan AM, Cheng S, Magnusson M, Larson MG, Newton-Cheh C, McCabe EL, Coviello AD, Florez JC, Fox CS, Levy D, Robins SJ, Arora P, Bhasin S, Lam CS, Vasan RS, Melander O, Wang TJ. Cardiac natriuretic peptides, obesity, and insulin resistance: evidence from two community-based studies. J Clin Endocrinol Metab. 2011; 96:3242–9.

Kim F, Biggs ML, Kizer JR, Brutsaert EF, de Filippi C, Newman AB, Kronmal RA, Tracy RP, Gottdiener JS, Djoussé L, de Boer IH, Psaty BM, Siscovick DS, Mukamal KJ. Kim Brain natriuretic peptide and insulin resistance in older adults. Diabet Med. 2017; 34:235–8.

Walford GA, Ma Y, Christophi CA, Goldberg RB, Jarolim P, Horton E, Mather KJ, Barrett-Connor E, Davis J, Florez JC, Wang TJ, Diabetes Prevention Program Research Group. Circulating natriuretic peptide concentrations reflect changes in insulin sensitivity over time in the Diabetes Prevention Program. Diabetologia. 2014; 57:935–9.

Gruden G, Landi A, Bruno G. Natriuretic peptides, heart, and adipose tissue: new fndings and future developments for diabetes research. Diabetes Care. 2014; 37:2899–908.

Bao Y, Shang X, Zhou L, Hu R, Li Y, Ding W. Relationship between N-terminal pro-B-type natriuretic peptide levels and metabolic syndrome. Arch Med Sci. 2011; 7:247–56.

Li WY, Chiu FC, Chien YF, Lin JW, Hwang JJ. Association of amino-terminal pro-brain natriuretic peptide with metabolic syndrome. Intern Med.2011; 50:1143–7.

Olsen MH, Hansen TW, Christensen MK, Gustafsson F, Rasmussen S, Wachtell K, Borch-Johnsen K, Ibsen H, Jørgensen T, Hildebrandt P. N-terminal pro brain natriuretic peptide is inversely related to metabolic cardiovascular risk factors and the metabolic syndrome. Hypertension. 2005; 46:660–6.

Bruno G, Barutta F, Landi A, Pinach S, Caropreso P, Mengozzi G, Baldassarre S, Fragapani S, Civera S, Cavallo Perin P, Gruden G. Levels of N-terminal pro brain natriuretic peptide are enhanced in people with the uncomplicated metabolic syndrome: a nested case-control analysis of the population-based Casale Monferrato Study. Diabetes Metab Rese Rev. 2015; 31:360–7.

Bruno G, Landi A, Barutta F, Ghezzo G, Baldin C, Spadafora L, Schimmenti A, Prinzis T, Cavallo Perin P, Gruden G. NH2-terminal pro-brain natriuretic peptide is a stronger predictor of cardiovascular mortality than C-reactive protein and albumin excretion rate in elderly patients with type 2 diabetes: the Casale Monferrato population-based study. Diabetes Care. 2013; 36:2677–82.

Tarnow L, Gall MA, Hansen BV, Hovind P, Parving HH. Plasma N-terminal pro-B-type natriuretic peptide and mortality in type 2 diabetes. Diabetologia. 2006; 49:2256–62.

von Scholten BJ, Reinhard H, Hansen TW, Lindhardt M, Petersen CL, Wiinberg N, Hansen PR, Parving HH, Jacobsen PK, Rossing P. Additive prognostic value of plasma N-terminal pro-brain natriuretic peptide and coronary artery calcifcation for cardiovascular events and mortality in asymptomatic patients with type 2 diabetes. Cardiovasc Diabetol. 2015;14:59.

Sanchez OA, Bahrami H, Daniels LB, Folsom AR, Lima JA, Maisel A, Peralta CA, Jacobs DR. The associations between metabolic variables and NTproBNP are blunted at pathological ranges: the Multi-Ethnic Study of Atherosclerosis. Metabolism. 2014;63:475–83.

Wang TJ, Larson MG, Keyes MJ, Levy D, Benjamin EJ, VasanRS. Association of plasma natriuretic peptide levels with metabolicrisk factors in ambulatory individuals. Circulation 115:1345-1353, 2007.

Sezen Y, Bas M, Demirbag R, Yildiz A, Celik H, Aksoy S. Nterminalpro-brain natriuretic peptide in cases with metabolic syndrome and its relationship with components of metabolic syndromeand left ventricular mass index. Clin Biochem 42: 1500-1503, 2009.

Wang TJ, Larson MG, Levy D, et al. Impact of obesity on plasmanatriuretic peptide levels. Circulation 109: 594-600, 2004.

Sengenes C, Bouloumie A, Hauner H, et al. Involvement of acGMP-dependent pathway in the natriuretic peptide-mediatedhormone-sensitive lipase phosphorylation in human adipocytes. JBiol Chem 278: 48617-48626, 2003.

Kanda H, Kita Y, Okamura T, et al. What factors are associatedwith high plasma B-type natriuretic peptide levels in a generalJapanese population? J Hum Hypertens 19: 165-172, 2005.

Hanley AJ, Festa A, D’Agostino RB Jr, et al. Metabolic and inflammationvariable clusters and prediction of type 2 diabetes:factor analysis using directly measured insulin sensitivity. Diabetes53: 1773-1781, 2004.

Hwang JJ, Li HY, Shieh GJ, Chien YF, Hua CH, Lin JW. Illustratingthe roles of C-reactive protein in the development of the metabolicsyndrome in women--a cross-racial validation. NutrMetabCardiovasc Dis 18: 671-677, 2008.

Suryasa, I. W., Rodríguez-Gámez, M., & Koldoris, T. (2021). Health and treatment of diabetes mellitus. International Journal of Health Sciences, 5(1), i-v. https://doi.org/10.53730/ijhs.v5n1.2864